trial

L-arginine in Treatment as Usual in Schizophrenia

NCTId NCT00718510
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 13 (actual)
Sponsored by University of Alberta
Primary completion 2011-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
13 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2009-09
Primary completion
2011-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
L-Arginine

Sponsors

University of AlbertaLead Sponsor
Alberta Health servicesCollaborator

Investigators

7
Serdar Dursun, M.D., Ph.D.Principal Investigator
Glen Baker, Ph.D., D.Sc.Principal Investigator
John W. Newcomer, M.D.Principal Investigator
Phil Tibbo, F.R.C.P.C.Principal Investigator
Mee-Sook Song, Ph.D.Principal Investigator
Pierre Flor-Henry, F.R.C.P.C.Principal Investigator
Diane Cox, Ph.D.Principal Investigator

Sites

1 total
Edmonton, Canada

Facts & assertions

4 sourced
Enrollment
13
Phase
NA
Primary Completion Date
2011-07
Status
COMPLETED
relationships
The graph out of here
drug
L-Arginine
drug
lead_sponsor
University of Alberta
company
collaborator
Alberta Health services
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Serdar Dursun, M.D., Ph.D.
person
Glen Baker, Ph.D., D.Sc.
person
John W. Newcomer, M.D.
person
Phil Tibbo, F.R.C.P.C.
person